In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Epimmune Inc.

http://www.epimmune.com

Latest From Epimmune Inc.

European Biotech Is Specialty Pharma

Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.

BioPharmaceutical Europe

A Really Near-Term Application for Discovery Technology: Momenta and Sandoz Attempt a Biogeneric

The press release was foggy; Sandoz Inc., the generics unit of Novartis AG, was teaming up with a biotech, Momenta Pharmaceuticals Inc. to commercialize "complex pharmaceutical products." Upon closer examination, the deal in fact has wide-ranging implications, representing the very real near-term possibility of a true generic biologic,

BioPharmaceutical

Anosys Inc.

As a former head of discovery research at Rhone-Poulenc Rorer Inc. (now Aventis SA), Jean-Bernard Le Pecq, PhD was accustomed to learning of new discoveries on a regular basis. But in 1997, one particular breakthrough in cell-to-cell communications caught his attention. Researchers found that small vesicles, known as exosomes, allow for the transfer of proteins to other cells. Le Pecq believed that exosomes could be used as a mechanism to develop innovative therapeutic vaccines and this idea ultimately propelled him to co-found Anosys Inc. in 1997.

BioPharmaceutical Business Strategies

Second-Generation Proteins

A steadily growing group of companies is using a variety of technologies to help shorten the path from platform to product company by creating improved versions of known and, in some instances, already marketed therapeutic proteins. Companies like Neose, Genencor, Applied Molecular Evolution and Maxygen, hope that by starting out with molecules already known to possess therapeutic properties, they can reduce the risks normally associated with drug discovery and development. The technologies employed by these second-generation protein players vary widely: from new methods, like directed evolution, to refinements of older ones such as glycosylation modification and PEGylation. And their business models run the gamut from a pure human therapeutic focus to the use of protein engineering in agriculture, industrial chemicals, as well as health care. But the fact remains for each of these companies that, whatever the improved odds for success afforded by second-generation protein work, they're still in a very risky business where more than half of their programs will fail. And, at least when it comes to the small universe of already marketed drugs, there will be plenty of competition among the companies. Still, there may be plenty of lucrative service opportunities to go around, as biotechs desperate for pipeline diversification, and with money to spend, look for ways to fully exploit the potential of their protein drugs.

BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register